在2025年10月3日发表的一项研究中,AI迅速发现了内醇林,一种新的抗生素,它针对克罗恩氏症相关的肠道细菌,而不会伤害有益的微生物. AI rapidly discovered enterololin, a new antibiotic that targets Crohn’s-linked gut bacteria without harming beneficial microbes, in a study published October 3, 2025.

人工智能加速了新抗生素 - - 肠道素的发现,该抗生素可以在不破坏有益微生物的情况下,针对与克罗恩病相关的有害肠道细菌. AI has accelerated the discovery of a new antibiotic, enterololin, which targets harmful gut bacteria linked to Crohn’s disease without disrupting beneficial microbes. 由麻省理工学院和麦克马斯特大学的研究人员开发 使用一种基因化的人工智能模型DiffDock, 发现该化合物在100秒内 与关键的细菌蛋白综合体LolCDE粘合在一起。 Developed by researchers at MIT and McMaster University using a generative AI model called DiffDock, the compound was found to bind to a key bacterial protein complex, LolCDE, in just 100 seconds. 实验室和老鼠研究证实,在保护微生物、优于传统抗生素的同时,它在减少炎症和有害细菌方面是有效的。 Lab and mouse studies confirmed its effectiveness in reducing inflammation and harmful bacteria while preserving the microbiome, outperforming traditional antibiotics. AI驱动的洞察力极大地缩短了开发时间和成本,代表了精确抗生素设计方面的一大进步。 The AI-driven insight cut development time and cost significantly, representing a major advance in precision antibiotic design. 调查结果于2025年10月3日在《自然微生物学》上发表。 The findings were published in Nature Microbiology on October 3, 2025.